The EMA medicines committee has recommended Foundayo (orforglipron) for adult weight management and type 2 diabetes. Orforglipron is a small non-peptide molecule that activates the GLP-1 receptor and is designed as a once-daily tablet.
Illustrative image — not a photograph of study participants or study data.EMA based the weight-management recommendation on studies involving more than 4,740 adults. After 72 weeks, participants taking Foundayo lost around 5% to 11% of body weight depending on dose, compared with around 2% to 2.5% with placebo. The most common side effects were nausea, vomiting and diarrhoea. A European Commission decision is still required before EU-wide authorisation.
Save peptides, build plans, set reminders and keep track of your own supplies in a private My Explorer space.